Kyle R Crassini
7PUBLICATIONS
4CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (7)
Sort by Publication Date:
|Jul 27, 2025
Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton's tyrosine kinase inhibitors.Mary Ann Anderson, Farrukh T Awan, Leanne Berkahn
|Dec 09, 2023
Pathogenesis and management of immune dysfunction secondary to B cell haematological malignancies.Kyle Crassini, John Gibson
|Jul 18, 2022
The ClpP activator ONC-212 (TR-31) inhibits BCL2 and B-cell receptor signaling in CLL.Narjis Fatima, Yandong Shen, Kyle Crassini
|Aug 01, 2019
Molecular pathogenesis of chronic lymphocytic leukaemia.Kyle Crassini, William S Stevenson, Stephen P Mulligan
|Jul 07, 2018
The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment.Kyle Crassini, Yandong Shen, Michael O'Dwyer
|May 17, 2018
MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment.Kyle Crassini, Yandong Shen, William S Stevenson
Pageof 2
